These results are consistent with the findings of this study in DLBCL patients, suggesting that TIGIT+ γδ T cell subtypes are characterized by high expression of TIGIT and low expression of CD226. In contrast to TIGIT, CD226 plays a pivotal role in the initiation and stimulation of T cells, thereby augmenting their cytotoxicity, particularly in the presence of PVR-expressing within tumor microenvironment. Here, PVR is linked to neoplasm.